Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2026)
Monopar Therapeutics (MNPR) posted Enterprise Value of -$61.8 million for Q4 2025, up 51.57% sequentially from -$127.7 million in Q3 2025, and down 34.96% YoY from -$95.1 million in Q4 2024.
Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Enterprise Value for 10 years, with the latest figure at -$61.8 million in Q4 2025.
- Quarterly Enterprise Value fell 34.96% year-over-year to -$61.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$61.8 million (down 34.96% YoY) and the FY2025 annual result came in at -$61.8 million, down 34.96% from the prior year.
- Enterprise Value improved to -$61.8 million in Q4 2025 per MNPR's latest filing, from -$127.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$5.5 million in Q3 2023 and troughed at -$127.7 million in Q3 2025.
- A 5-year average of -$25.7 million and a median of -$17.1 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value soared 60.39% in 2023, then sank 2020.86% in 2025.
- Over 5 years, Enterprise Value stood at -$20.0 million in 2021, then soared by 59.1% to -$8.2 million in 2022, then increased by 11.24% to -$7.3 million in 2023, then slumped by 530.55% to -$45.8 million in 2024, then plunged by 34.96% to -$61.8 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$61.8 million, -$127.7 million, and -$39.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -52.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.76 Mn |
| Dec 31, 2025 | -61.83 Mn |
| Sep 30, 2025 | -127.68 Mn |
| Jun 30, 2025 | -39.50 Mn |
| Mar 31, 2025 | -39.71 Mn |
| Dec 31, 2024 | -45.82 Mn |
| Sep 30, 2024 | -6.02 Mn |
| Jun 30, 2024 | -6.12 Mn |
| Mar 31, 2024 | -7.81 Mn |
| Dec 31, 2023 | -7.27 Mn |
| Sep 30, 2023 | -5.52 Mn |
| Jun 30, 2023 | -7.21 Mn |
| Mar 31, 2023 | -10.42 Mn |
| Dec 31, 2022 | -8.19 Mn |
| Sep 30, 2022 | -13.92 Mn |
| Jun 30, 2022 | -16.46 Mn |
| Mar 31, 2022 | -17.82 Mn |
| Dec 31, 2021 | -20.01 Mn |
| Sep 30, 2021 | -21.98 Mn |
| Jun 30, 2021 | -24.29 Mn |